Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy

Neoadjuvant chemotherapy (NAC) is a commonly utilized strategy for the treatment of early-stage triple-negative breast cancer (TNBC). A major advantage of this strategy is the ability to observe the tumor response to chemotherapy. Pathologic complete response (pCR) is a well-established end point of NAC clinical trials, and serves as a useful prognostic marker as pCR is independently associated with improved survival outcomes compared with patients without pCR [2].